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Abstract
Glycine is the major inhibitory neurotransmitter in the spinal cord and some brain regions. The presynaptic glycine
transporter, GlyT2, is required for sustained glycinergic transmission through presynaptic reuptake and recycling of glycine.
Mutations in SLC6A5, encoding GlyT2, cause hereditary hyperekplexia in humans, and similar phenotypes in knock-out mice,
and variants are associated with schizophrenia. We identified a spontaneous mutation in mouse Slc6a5, caused by a MusD
retrotransposon insertion. The GlyT2 protein is undetectable in homozygous mutants, indicating a null allele. Homozygous
mutant mice are normal at birth, but develop handling-induced spasms at five days of age, and only survive for two weeks,
but allow the study of early activity-regulated developmental processes. At the neuromuscular junction, synapse elimination
and the switch from embryonic to adult acetylcholine receptor subunits are hastened, consistent with a presumed increase
in motor neuron activity, and transcription of acetylcholine receptors is elevated. Heterozygous mice, which show no
reduction in lifespan but nonetheless have reduced levels of GlyT2, have a normal thermal sensitivity with the hot-plate test,
but differences in repetitive grooming and decreased sleep time with home-cage monitoring. Open-field and elevated plus-
maze tests did not detect anxiety-like behaviors; however, the latter showed a hyperactivity phenotype. Importantly,
grooming and hyperactivity are observed in mouse schizophrenia models. Thus, mutations in Slc6a5 show changes in
neuromuscular junction development as homozygotes, and behavioral phenotypes as heterozygotes, indicating their
usefulness for studies related to glycinergic dysfunction.
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Introduction
In the mammalian nervous system, inhibitory synaptic trans-
mission is primarily mediated by vesicular release of gamma-
aminobutyric acid (GABA) and glycine. GABAergic neurons
predominate in the forebrain, while glycinergic neurons are
primarily found in the brain stem and the spinal cord. However,
inhibitory synaptic transmission is complicated, including exam-
ples such as the co-expression of GABA and glycine, and the role
of glycine in particular needs further elucidation to determine its
full impact in inhibitory circuitry, its role in neurological diseases,
and its potential as a target for therapy.
In the spinal cord, motoneurons receive inhibitory connections
from Renshaw cells, propriospinal interneurons, and brain stem
projections [1,2]. Renshaw cells are activated by axon collaterals
of motoneurons innervating proximal muscles, and form a feed-
back loop onto the activating motoneuron or synergistic moto-
neurons (recurrent inhibition) [3–6]. Propriospinal interneurons
relay inputs from the muscles or joints, and can connect directly,
or via other spinal interneurons, to the motoneurons. Descending
inputs from the ventromedial medulla also contribute GABA/
glycinergic inhibition on the motoneurons [7]. Therefore, direct or
indirect glycinergic inhibition onto spinal motoneurons modulates
their excitability, and consequently, voluntary movements, central
pattern generators responsible for locomotion and breathing, the
strength of muscle contractions, and muscle relaxation.
In the sensory circuits of the dorsal horn of the spinal cord,
glycinergic inhibition, often in association with GABAergic inhibi-
tion [6,8], regulates the sensitivity to painful stimuli [9]. Glyciner-
gic interneurons in different laminae of the dorsal spinal cord
inhibit the transmission of low intensity stimuli to the brain.
Pharmacological disinhibition of the spinal cord increases pain
sensitivity (hyperalgesia) [10,11], and modification of the glyci-
nergic transmission in cases such as neuropathic pain, makes
innocuous stimuli painful (allodynia) [12].
In the brain, most synaptic inhibition is mediated by GABA,
but glycinergic terminals are found in low abundance in the
thalamus, hypothalamus, cortex and cerebellum and in high
abundance in the brain stem and cerebellum [13]. The role of
glycinergic transmission in the brain is less understood, and is
complicated by the fact that glycine can be co-released with
GABA [14], can be released by astrocytes [15] and can diffuse
(spill-over) from inhibitory synapses and potentiate NMDA
receptors [16,17].
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mechanisms, and classically acts on its postsynaptic receptors,
which are ligand-gated pentameric chloride channels [18]. Glycine
is cleared from the synaptic cleft by two glycine transporters,
GlyT1 (Solute carrier, family 6, member 9, Slc6a9) found primarily
on astrocytes, and GlyT2 (Solute carrier, family 6, member 5,
Slc6a5), found primarily on presynaptic terminals [19]. GlyT1
terminates glycinergic transmission by clearing glycine from the
synapse, whereas GlyT2 is needed to sustain prolonged glycinergic
transmission through presynaptic reuptake and vesicle reloading in
the inhibitory presynaptic terminal [20]. The localization of
GlyT2 to glycinergic terminals [13] makes it a reliable marker of
glycinergic neurons and a target of choice to specifically alter
glycinergic synaptic transmission.
Genetic experiments in mice and elucidation of congenital
disorders in humans have confirmed and refined the understand-
ing of glycinergic transmission gained by histological and phar-
macological approaches. Mice lacking Slc6a9 expression display an
absence of muscle tone and irregular breathing. On in vitro
preparations of the brain stem, containing the respiratory network,
Slc6a9 mutants display prolonged inactivity instead of the
repetitive firing pattern observed in wild-type animals, and this
defect is reversed by the GlyR blocker strychnine. These obser-
vations together indicate that loss of GlyT1 leads to an excessive
spinal glycinergic inhibition, and prove the requirement of GlyT1
in the clearance of glycine from the extracellular milieu [21].
Alterations of SLC6A9 are suspected to cause glycinergic encep-
halopathy in humans, although no mutation in patients has been
detected to date [22]. In contrast, mice lacking Slc6a5 expression
have muscle tremors and generalized spasms [23] and recordings
from the spinal cord motoneurons revealed a strong reduction of
the miniature inhibitory currents amplitude, indicating a lack of
glycinergic inhibition, consistent with the requirement of GlyT2
for the reuptake and recycling of glycine at the presynaptic
terminal. In humans, SLC6A5 mutations cause a similar phenotype
of perinatal hyperekplexia, a condition characterized by stiff
muscles [24,25]. Mutation or deletion in Slc6a5 also causes
postnatal handling- or noise-induced myoclonus in calves [26] and
muscle stiffness and tremor in canine puppies [27], phenotypes
very similar to those observed in mice. Similarly, defects in another
component of the glycinergic pathway, gephyrin, cause loss of
glycine receptors from the synapse and rigidity of neonatal mice,
consistent with an absence of glycinergic inhibition [28] and stiff
man syndrome and related disorders in humans [29,30]. Sur-
prisingly, while mutations in Slc6a5 are lethal postnataly in mice,
dogs and cows, they only cause a transient, postnatal muscle
stiffness in humans that disappears in the first year and only
reappears with lower severity in conjunction with an increased
startle response in adults with hyperekplexia. The lethality in other
organisms appears to result from the extreme spasticity in response
to voluntary movement, which eventually prohibits even basic
behaviors, whereas with care, humans can eventually compensate
with increased GABAergic inhibition.
In regard to modulation of pain sensitivity by glycine, the
alpha3 glycine receptor was found to specifically mediate spinal
cord processing of nociception and prostaglandin-mediated pain
sensitization [31] and mice lacking alpha3 were immune to
inflammatory pain sensitization. Consistently, activation of alpha3
GlyRs has also been shown to mediate the cannabis analgesic
effects independent of the cannabinoid receptors [32].
In addition to the anticipated effects on muscle tone resulting
from changes in glycinergic transmission in the spinal cord, glycine
is increasingly implicated in higher behavioral functions and
neuropsychiatric disorders. Local brain delivery of strychnine, a
glycine receptor blocker, has been shown to be anxiolytic in rats
[33]. Interestingly, adult mice heterozygote for the Slc6a9 knock-
out or with a targeted deletion of Slc6a9 in the forebrain neurons,
are free of any muscle tremor, but display an increase in spatial
memory, a decrease in the sensitivity to amphetamine in the
disruption of prepulse inhibition [34], better Pavlovian aversive
conditioning, and better learning abilities in a special paradigm
[35]. To date, no cognitive phenotype has been associated
with Slc6a5 in mice ; in humans, although first studies found no
association between SLC6A5 variations and schizophrenia [36],
SNPs in the SLC6A5 gene have been associated with schizophrenia
in the Japanese population [37]. Some of these phenotypes may
not be related to changes in inhibition, but instead to the role of
glycine in potentiating NMDA receptors. For instance, a partial
agonist of the glycine-binding site on the NMDA receptor, D-
cycloserine, has also been shown to be mildly anxiolytic and a
stimulant [38]. Therefore, additional behavioral testing in animal
models that perturb glycinergic transmission is warranted.
In this study, we have found a new, spontaneous loss-of-function
allele of Slc6a5 in mice. The overt phenotype of handling induced
muscle rigidity is similar to the previously described phenotype in
the knockout strain. We were able to use this mutation as a
homozygote to study the impact of changes in motoneuron
excitability in the developmental processes of synapse elimination
and maturation at the neuromuscular junction. We were also able
to study the mutation as a heterozygote to determine the effects of
reduced GlyT2 levels on sensory function and behavior. We
conclude that glycinergic pathways, and GlyT2 in particular, are
candidate targets for therapeutic interventions for multiple
behavioral phenotypes related to neuropsychiatric conditions.
Results
Mapping and characterization of a new Slc6a5 mouse
mutant
Mice with a putative spontaneous mutation were noted in an
inbred NOD.129S2(B6)-Cd8a
tm1Mak/DvsJ colony maintained at
The Jackson Laboratory. This strain is typically used as a control
strain for type 1 diabetes research, it does not develop a diabetic
phenotype and does not have overt neuromuscular phenotypes.
However,asubsetofthesemicedisplayedgeneralizedmusclespasms
and stiffness, particularly in response to handling (Fig. 1.A and
Movie S1) around 5 days after birth, lower body weight first
noticeable at P5 (Fig. 1.B), and survived only two weeks postnatally.
Affectedmicerepeatedlyaroseinthelittersobtained fromunaffected
parents at approximately one in four, suggesting a heritable defect
caused by a single recessive locus. We therefore undertook a
standard F2 mapping cross with DBA/2J as the wild type mapping
partner (see methods). In the F2 progeny of this cross, the stiffness
phenotype partially co-segregated with the white coat color caused
bytherecessivealbinomutationofthetyrosinase(Tyr)geneintheNOD
strain(the DBA/2J miceare Agouti), at 94.6 Mbon Chromosome 7.
Of 95 F2 pups, 34% were affected, and 69% of the affected pups
were albino, whereas only 8% of the non-affected pups were albino.
The association with Chr. 7 was further confirmed by standard
genetic mapping with simple sequence length polymorphism (Mit)
markers using 16 affected and 19 unaffected littermate mice. This
further localized the mutation between 31.1 and 59 Mb on
chromosome 7, segregating with D7Mit27 at 51.2 Mb in all mice
examined (Fig. 1.C). Of all the genes documented by the Mouse
Genome Informatics website in this region, Slc6a5, encoding GlyT2,
at 57.2 Mb on the Chromosome 7 (Fig. 1.D), was selected for closer
analysis because of the similarity of the phenotypes of the new
mutant and the published Slc6a5 knockout allele [23].
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quantitative RT-PCR from mutant and control brain mRNAs.
Partially overlapping reactions were designed to amplify cDNA
sequences encoded by exons 1 to 2, exons 2 to 7, exons 7 to 13 and
exons 12 to 16 (Fig. 2.A). The reaction amplifying exons 2 to 7
produced two bands of near normal size and a third, very small
band in the mutant mice presumed to be homozygous, but only
one band in the wild-type (Fig. 2.B). When sequenced, the product
similar in size to the wild type product was indeed indistinguish-
able from the reference sequence of C57BL/6J mice. However,
the longer product included an insertion of 183 bp between exons
5 and 6 (Fig. 2.C). Using a BLAST search, these 183 bp were
found to be perfectly homologous to the MusD LTR-retro-
transposon [39](Fig. 1.C). A reverse primer in the 59 region of the
183 bp retrotransposon insert (primer MusD R in Fig. 2.C) and
forward primers in intron 5 of Slc6a5 were used for amplification
from genomic DNA of homozygote mutants. One of the forward
primers (int5 F, Fig. 2.C) produced an amplification product.
Sequencing showed that the retrotransposon inserted in the
sequence of intron 5 at 1,833 base pairs. PCR on genomic DNA
using primers flanking this site (int5 F and int5 R, Fig. 2.C),
amplified a anticipated, 3 kb product from control mice, but a
9.5 kb product was amplified from homozygous mutant mice
(Fig. 2.D). Based on sequence from the 59 end of the 9.5 kb
product, the difference in size was accounted for by an almost
complete MusD retrotransposon. Taken together, these data
indicate that the retrotransposon inserted in intron 5 contains
splice donor and acceptor sites, resulting in a 183 bp fragment of
the transposon being spliced into the mRNA of Slc6a5 between
exons 5 and 6 (Fig. 1.C). The insertion does not modify the
splicing of the neighboring exons 2, 3, 4 and 7 (Fig. 1.B).
The effects of the MusD insertion were unclear since the 183 bp
insertion preserves the reading frame of Slc6a5, wild type cDNA
without the insertion was still detected (Fig. 2.B), and the RT-PCR
used to find the mutation was not quantitative. Therefore, we
analyzed Slc6a5 mRNA and protein levels in the mutant mice.
Quantitative RT-PCR on spinal cord cDNAs with primers
designed on the 39 end of the Slc6a5 cDNA, downstream of exon
5, showed a reduced amount of transcript in the heterozygotes and
a virtually undetectable level in the homozygote mutants (data not
shown). By western blot, GlyT2 was detected at very low levels in
the brains of wild-type animals (data not shown) but was readily
detectable in spinal cord extracts (Fig. 2.E). In the mutant mice, no
protein was detected with the antibody recognizing the C-terminal
part of the protein, suggesting that the intronic insertion either
interferes with the translation of Slc6a5 or destabilizes Slc6a5
transcripts and creates a null mutation. Importantly, in mice
heterozygous for the mutation, the amount of GlyT2 protein was
Figure 1. Overt phenotype and mapping of the new mutation. A. P15 mutant (left, white) and unaffected littermate (right, brown) in the NOD
x DBA/2 mapping cross. Picture was taken at the time of a generalized tremor of the mutant. B. Growth curve for wild-type, heterozygous and
homozygous mutants, completed once the genotyping assay was established. C. Haplotype of affected (left) and unaffected (right) mice at three loci
of chromosome 7 flanking the Slc6a5 (Slc6a5) gene. Simple sequence length polymorphism (Mit markers) different in NOD and DBA/2 and their
positions in megabases (Mb) are indicated. The number of mice of each genotype is indicated below the diagram. D. Schematic representation of
chromosome 7 with centromere at the top, location of MIT markers used and Slc6a5. Positions are given in megabases (Mb) on the left and
centimorgans (cM) on the right.
doi:10.1371/journal.pone.0030217.g001
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Using immunocytochemistry, GlyT2 was detectable in sagittal
brain sections of wild type mice in the olive nuclei of the brainstem
and the spinal cord, consistently with previous reports [40–41].
Brains and spinal cords from mutant mice were devoid of any
detectable signal, confirming that the new Slc6a5 mutation is a
severe hypomorph or null allele (Fig. 2.F). This allele has been
formally designated Slc6a5
m1J by the Mouse Genome Informatics
group at The Jackson Laboratory.
Disinhibition of the spinal cord results in hastened
neuromuscular junction maturation
Slc6a5 is abundantly expressed in the ventral spinal cord and is
required for the re-uptake of glycine and refilling of synaptic
Figure 2. Characterization of the new Slc6a5 mutation as a null-allele. A. Schematic of the Slc6a5 gene organization, with boxes and lines
representing exons and introns respectively, and boundaries of PCRs (1 to 4) run on reverse-transcribed cDNAs. B. Agarose gel of the PCR amplification
products from cDNA. Note the extra band in PCR 2 on mutantbrain cDNAs (arrow). C. Schematic representation of intron 5,andlocation of theinsertion
and splice donor and acceptor sites in the retrotransposon sequence. The 10 base pairs immediately 59 of the insertion site, 1833 bp into intron 5, are
shown,as well as thefirstbase-pairs oftheLTRelementoftheretrotransposon. The183 bpsequenceofthetransposon that isspliced-in Slc6a5 mRNA is
indicated with its 10 first andlast base-pairs andthe inferred acceptor anddonor splice sites. Theprimers used to localize the insertion (int5Fand MusR),
and to amplify the transposon from mutant genomic DNA (int5F and int5R) are indicated by arrows. D. Agarose gel of the products of the PCR on
genomic DNA with primers flanking the insertion site (int5F/R of C.). A 3 kb product was amplified from wild-type gDNA, but only a 9 kb product was
amplified from mutant gDNA. E. Anti-GLYT2 Western blot on spinal cord cell membrane preparations, with beta-dystroglycan used as a loading control.
Genotypesareindicatedabovetheblot.F.Anti-GLYT2 immunocytochemistry(DAB)onbrainsagittalsectionsandspinalcordcrosssections.Nucleiwere
counterstainedwith hematoxylin beforemounting. Thelateral brain stem is shown in thetop panelswith the ventral lobules of the cerebellumvisible in
the top right corners and the ventral horn of the spinal cord in shown in the bottom panels.
doi:10.1371/journal.pone.0030217.g002
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GlyT2, sustained glycinergic inhibitory transmission is impaired.
Motoneurons are normally under strong inhibition (reviewed in
[2], part of which provides the negative feed-back necessary to end
the volleys of action potentials that trigger muscle contractions.
Therefore, in the absence of glycinergic inputs, motoneurons are
more excitable and are presumed to fire excessively and without
coordination, resulting in severe muscle spasms. The muscle
tetanus phenotype observed in the Slc6a5 mutants is consistent
with such an overactivity of motoneurons (Movie S1), although we
were unable to monitor motor neuron activity in vivo in response to
either spontaneous or voluntary activation in unanesthetized mice.
Nonetheless, this mutation allows the study of the role of increased
motoneuron excitability on the maturation or maintenance of
the neuromuscular system. We investigated the effects of this
overactivity on two postnatal developmental features of the NMJ
that had not been previously examined in the Slc6a5 knock-
out mice: synapse elimination, and the molecular switch of the
acetylcholine receptor subunit expression from the embryonic
gamma subunit to the adult epsilon subunit.
In rodents, NMJs are innervated by more than one motor axon
terminal at birth. During the first two postnatal weeks, pruning of
extranumerary axonal branches eventually results in neuromus-
cular junctions with their adult form, a single terminal from a
motoneuron connecting to a single postsynaptic site on the muscle
fiber [42]. This process of synapse elimination has been shown to
be hastened by electrical stimulation of the motor nerves [43] but
few in vivo, non-invasive alternatives exist to endogenously modify
the activity of the motoneurons [44].
Therefore, we quantified synapse elimination in the triangularis
sterni muscle (Fig. 3.A), a flat muscle from the inner wall of the rib
cage where NMJs can be clearly visualized. At P3, about 75% of the
NMJs were polyinnervated, with the same number of extranumer-
ary terminals per NMJs in both wild-type and mutant animals (50%
of NMJs receiving 2 axon terminals, 20% of NMJs, 3 terminals and
5%of NMJs, 4 terminals,datanotshown), and theelimination ofall
but one axonal branch was completed by P12 for both the mutants
and wild-type (Fig. 3.B). However, the course of the elimination in
the mutant mice significantly preceded that of their wild-type
littermates after P5. The NMJs themselves were indistinguishable in
size and AChR labeling intensity at P6-7, but a trend towards
smaller NMJs with stronger labeling was evident in P9-11 samples
(area: WT 166.6610.2 mm
2, mut 141.4610.4, T-test p=0.16,
labeling intensity 154.6+/25.5 arbitrary units, 171.6+/27.9, p=
0.13 in samples from 4 mice of each genotype at each age).
Acetylcholine receptor expression is indeed another aspect of
neuromuscular junction maturation, particularly the developmen-
tal switch from the gamma acetylcholine receptor subunit to the
epsilon subunit (Fig. 3.C) [45–47]. This molecular switch results in
the change of the AChR conductance required for the
maintenance of the NMJs postnatally [48]. Experiments in vitro
suggested thatactivitymightregulate thisdevelopmentalswitch[49]
Figure 3. Neuromuscular junction phenotypes. A. Representative pictures of P7 NMJs in WT (left) and mutant (right) triangularis sterni muscles.
The axons are labeled by the Thy1-YFP16 transgene (green) and the acetylcholine receptor plaques by fluorescent alpha-bungarotoxin (red). NMJs
innervated by more than one axon terminal (arrowheads) are more abundant in the WT than in the mutant. B. Time course of the synapse
elimination. The curves represent the average percentage of polyinnervated NMJs in wild-type (gray) and mutant (black) triangularis sterni muscles at
ages P3 to P12. a: Wilcoxon signed-rank paired test, p=0.09. The bars represent the average percentage of polyinnervated NMJs in the P3-P5 and P6-
P9 age groups. * : Mann-Whitney test, p,0.05. Error bars represent the SEM. C. Schematic representation of the molecular switch from gamma to
epsilon AChR subunits in the muscle pentameric acetylcholine receptor, also indicating the constitutive subunits alpha, beta and delta. D.
Quantification of the fold-change of AChR subunits alpha, gamma and epsilon, and myogenin, in P5 and two week old synaptic regions of the mutant
diaphragm, expressed as a ratio to age-matched WT values (=1.0). Biological replicates: 5 for P5, 7 for two week. Error bars represent the confidence
interval. * : Mann-Whitney test, p,0.05.
doi:10.1371/journal.pone.0030217.g003
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increaseinepsiloninnewbornmice [50].However,theeffectsofthe
reciprocal increase in axonal activity are less well studied in vivo.
We used syber-green QPCR to quantify the relative abundance
of different AChR subunits in wild-type and mutant mice, at P5, an
age when the switch from gamma to epsilon is actively taking place,
and at two weeks, when epsilon has completely replaced gamma in
wild type mice. No significant change in the AChR subunit
expression was detected at P5. At 2 weeks, alpha and epsilon AChR
subunits were expressed at higher level in the mutant muscle than in
the control (Fig. 3.D). Alpha mRNAs were increased by almost
60%, and epsilon mRNA by 30%. Gamma mRNAs tended to be
decreased, but no statistical significance was obtained with the
sample size used. In wild type mice, the epsilon mRNA expression
increases from birth to P15 before decreasing to its adult levels,
whereas gamma mRNA decreases from birth to P15 [50]. The
overexpression of epsilon and the slight reduction of gamma in the
Slc6a5 mutants are consistent with a hastened maturation of the
NMJs. However, the elevated levels of alpha mRNAs in the Slc6a5
mutants also suggest that the increased excitability of motoneurons
drives a non-specific increase of postsynaptic transcription of the
AChR subunits. Myogenin, among other myogenic factors,
positively regulates the transcription of alpha and gamma AChR
subunits [51–53] but is negatively regulated by innervation and
electrical activity [54–57]. The increase in AChR subunit
transcription is not consistent with the expected decrease of
myogenin resulting from an increased activity. We therefore also
measured the variations in myogenin RNA levels and found that at
P5 and two weeks, myogenin levels were decreased by 25% and
50%, respectively, at these ages in the Slc6a5 mutants (Fig. 3.D).
This is consistent with an increase in motoneuron activity,
indicating that hyperactivity of motoneurons in vivo positively
regulates AChR transcription in a myogenin-independent way.
No change in pain sensitivity in Slc6a5 heterozygotes
Western blot analysis revealed that the levels of transporter are
reduced by half in mice heterozygous for the Slc6a5 mutation
(Fig. 2.E). The consequences of this reduction are untested, but
may differ from the complete loss of function in the homozygotes.
A reduction in GlyT2 may diminish glycine re-uptake from the
synaptic cleft, without hampering the neurotransmission itself.
This would result in a longer half-life of glycine in the extracellular
space, and an increased inhibition of the postsynaptic neurons
through the increase of hyperpolarizing currents mediated by the
glycine receptors. Slc6a5 heterozygotes, therefore, could mimic the
partial blockade of GlyT2 achieved pharmacologically. The
specific GlyT2 blocker ALX1393 was recently shown to have
antinociceptive effects in the rat [58]. We therefore compared
thermal nociception between mice heterozygous for the Slc6a5
mutation and wild-type littermates using a hotplate assay to
determine if Slc6a5 heterozygotes had a phenotype consistent with
pharmacologically reduced GlyT2 activity. The delay in paw
retraction in response to heat was not significantly different in the
heterozygous mice (Fig. 4). In older mice, a slight but non-sig-
nificant increase in the retraction time was noticed (data not
shown). Thus, different effects on thermal nociception are obtained
in Slc6a5 heterozygous mice and ALX1393 treated rats.
Partial loss of GlyT2 increases grooming behavior and
context-dependent locomotion, but does not affect
anxiety levels
Slc6a5 is expressed at lower levels in the brain than in the spinal
cord. In addition to the brain stem, it has been detected in the
cerebellum, thalamus, the basal ganglia and the hippocampus by
immunocytochemistry [13]. Transgenic mice expressing a fluo-
rescent protein under the control of the Slc6a5 gene also provided
evidence for innervation of the amygdala and neocortex by a few
Slc6a5-positive fibers [41]. Given the reduced amount of
transporter in Slc6a5 heterozygotes, and the possibility that GlyT2,
by regulating extracellular glycine concentrations could modulate
NMDA receptors activation, we tested other behavioral effects of
reduced GlyT2. In particular, we wanted to examine phenotypes
relevant to schizophrenia and anxiety given the association
between SLC6A5 and NMDA receptors and these conditions in
humans.
Heterozygous and wild-type mice at six weeks and seven months
of age were used for these studies. In a first approach to detect
spontaneous, non-induced (context-independent) differences in
behaviors, mice housed individually were monitored over-night in
their cage. Videos were then analyzed using software able to
recognize and tabulate a large number of behaviors [59–61].
Many of the most frequent behaviors, such as horizontal locomo-
tion, hanging, searching, or consuming food were not significantly
different between the two genotypes (Fig. 5.A). However,
heterozygotes spent less time sleeping during the dark period,
their normal nocturnal activity phase, and more time grooming
(Fig. 5.B). When considered by itself, independently of the other
feeding behaviors, chewing was also more frequent in the young
heterozygotes (data not shown).
To study anxiety-related behaviors and activity, we used
openfield and elevated-plus-maze assays. In the openfield, the
arena is virtually divided into 5 concentric zones. Mice spend more
time in the most peripheral area (zone 1) than in the central area
(zone 5), an indicator of anxiety consistent with the known
apprehension of rodents to venture in open areas [62]. However,
there were no differences in the time spent (Fig. 6.A) or the track
length (Fig. 6.B) in each zone between the heterozygous and the
littermate control mice at either age, suggesting that a partial
Figure 4. Normal thermal nociception in heterozygotes. Results
of the hot-plate assay. Reaction time before flickering/retraction of one
paw after mice have been placed on a 50 deg hot plate. Individual
values are shown by circles, mean +/- SEM are shown by the chart and
error bars. The number of mice tested is indicated.
doi:10.1371/journal.pone.0030217.g004
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two opposing arms that are open and two opposing arms that are
enclosed. Anxiety in this test is reflected by an increase in the time
spent in the closed arms. Consistent with the open field results,
there was no difference in the time spent in the different arms
between the two genotypes (Fig. 6.C), indicating a normal anxiety
level in the heterozygotes. Surprisingly, heterozygotes displayed an
increased velocity that was significantly higher in the closed arm
for the 6 weeks old, and in the open arm for the 7 months old
group. This hyperactivity seems context-dependent since the
reduction in sleep time observed in the home cage monitoring was
not associated with a significant increase of locomotor behaviors,
and the openfield did not show an increase in track length, which
would indicate increased locomotor activity.
Discussion
We have identified a new mutation in the mouse Slc6A5 gene.
This mutation arose on an NOD genetic background, but
nonetheless shows many phenotypic similarities to previously
reported knockout animals. We were able to use these mice to
examine activity-dependent developmental processes at the
postnatal NMJ, and to explore the behavioral impacts of reduced
GlyT2 levels in viable heterozygous mice.
From a mouse genetics perspective, this mutation independently
confirms the severe phenotype of Slc6a5 mutations. Like the
knockout, this allele also appears to be a null, based on
undetectable protein levels. Importantly, the NOD background
does not appear to markedly alter the severity of the phenotype.
Also, the mutation is the result of a MusD retroviral insertion into
intron 5 of the gene, resulting in the inclusion of a 183 bp insert in
the Slc6a5 mRNA, but resulting in a complete loss of protein. The
MusD insertion is an interesting mechanism for a spontaneous
mutation and has only been reported in one previous case that we
are aware of [63]. MusD elements are closely related to ETn
elements, which are a common cause of insertional mutations in
mice. MusDs encode the proteins necessary for transposition,
whereas ETns do not. Thus MusD encoded proteins cause ETns
to mobilize, but the MusDs rarely mobilize themselves [64]. Our
sequencing is consistent with the intron 5 insertion being a MusD1
element, although the shorter size (6 kb versus 7 kb) raises the
possibility of an internal deletion of the retrotransposon in
Slc6a5
m1J.
The changes observed at the NMJ, including a hastening of
synapse elimination and a decrease in myogenin expression, are
anticipated for a mutation that would increase the firing activity of
motor neurons based on impaired glycinergic transmission in the
spinal cord, although we have been unable to directly record an
increase in motor neuron firing over time in unanesthetized
animals. The overt phenotypes of tetany in response to stimulation
and rigidity due to increased muscle tone are also consistent with
Figure 5. Nocturnal behavioral phenotypes in the home cage monitoring system. A. Table of the major behaviors that did not show any
change between genotypes, in % of the total nocturnal time (mean and SEM). B. Behaviors with a significant change. a : p=0.08 for the amount of
sleep and b : p=0.06 for the amount of grooming in the 7 months old mutants, * : p,0.05, ** : p,0.01, Mann-Whitney test. See ‘‘Methods’’ section
for more detailed description. 6 female mice per age group and genotype were observed.
doi:10.1371/journal.pone.0030217.g005
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phenotypes and the overt spastic phenotype are only visible after
P5, suggesting that the lack of glycinergic inhibition only affects
the excitability of motoneurons past a certain maturation stage.
Elevation in transcription of multiple AChR subunits including
both constitutive (alpha) and adult (epsilon) forms is surprising,
particularly in light of the decrease in myogenin expression. This
finding suggests an activity-dependent, myogenin-independent
mechanism that regulates AChR expression.
In other model organisms such as Drosophila, mutation that
effect excitability of the nervous system, such as Potassium channel
mutations, have been extensively used to study the contribution of
neuronal activity to developmental processes [65–67]. Our results
suggest that Slc6a5 mutations may be similarly useful for exploring
these relationships, particularly in the mammalian peripheral
nervous system and spinal cord.
The behavioral changes in heterozygous mice also provide a
valuable avenue for additional research. Glycine is increasingly
appreciated as an important neurotransmitter system in the brain
as well as the spinal cord, and variation in genes affecting
glycinergic transmission are associated with a variety of human
conditions. Glycine has two potential modes of action in the
brain. First, it can produce inhibitory chloride currents through
activation of classical pentameric glycine receptors. Second, it can
potentiate NMDA receptor activation through synaptic spill over.
We noted a normal response to thermal nociception, decreased
nocturnal sleep and increased grooming, and increased context-
dependent activity in a T-maze, but no anxiety phenotypes in
Slc6a5 heterozygous mice. The normal nociception suggests that
Slc6a5 heterozygotes do not have glycine reuptake defects as severe
as rats treated with GlyT2 inhibitors. The analgesic effect of
GlyT2 blockers in rats is consistent with the observation that
pharmacological blockade of GlyT2 in spinal cord sections
increases the decay time of evoked and spontaneous inhibitory
currents, i.e. increases extracellular glycine [68]. Although insuffi-
cient to effect pain sensitivity, a slight increase in extracellular
glycine could have other consequences in the brain, through the
glycine-dependent NMDA receptor potentiation. For instance,
decreased glycine transport has been shown to increase NMDA
receptor-mediated currents [68]. Effects of changing GlyT2
activity had not been tested in the brain previously, and our
behavioral phenotypes such as decreased sleep, hyperactivity
and repetitive behaviors were, to our surprise, not consistent with
increased glycinergic inhibition or NMDA receptor potentiation.
Hyperactivity and stereotypy have been observed in mice with
reduced amounts of NMDA receptors [69], or reduced NMDA
Figure 6. Anxiety-related behaviors. A, B : Openfield test, C, D : elevated plus-maze test. Wild-type and heterozygotes values are shown
for two age groups, 6 weeks and 7 months old. A. Average time spent per zone of the openfield, in sec., zone 1 being the most peripheral, zone 5 the
central zone. B. Average track length per zone (in inches) during the 10 min observation. C. Average time spent in the open or closed arm of the
elevated plus-maze. D. Average velocity in the open and closed arms. 6 mice per age group and genotype were observed. * : p,0.05, ** : p,0.01,
Mann-Whitney test.
doi:10.1371/journal.pone.0030217.g006
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site [70] or reduction of the synthesis of another endogenous
ligand of the glycine-binding site, D-serine [71]. These mice are
recognized models of schizophrenia, respond to schizophrenia
drug therapies and support the theory of NMDA receptor hypo-
function of schizophrenia (reviewed in [72] and [73]). The de-
crease in nocturnal sleep we observed in the Slc6a5 heterozygotes is
also reminiscent of the sleep disorders commonly associated with
schizophrenia [74]. Therefore, while mice heterozygous for
mutations in Slc6a9 show phenotypes consistent with reduced
glycine transport, such as increased glycinergic facilitation of
NMDA receptors and anti-schizophrenic effects [34,35], the mice
heterozygous for the mutation in Slc6a5 have behavioral phe-
notypes that could be explained by a reduced glycine secretion and
a decreased glycinergic facilitation of NMDA receptors in the
brain. In support of this interpretation, pharmacological GlyT2
blockade has been shown to not only increase extracellular glycine
concentration, but also have a presynaptic effect that could be
explained by a reduced cytosolic glycine concentration limiting the
synaptic vesicle release probability [68]. Our results, together,
suggest that reduced GlyT2 activity may have different effects in
the brain versus the spinal cord, or there may be a greater
contribution of NMDA receptor potentiation in one region versus
the other. However, the similar spectrum of behavioral changes
compared to other schizophrenia mouse models is intriguing
considering the association of a SNP near human SLC6A5 with
schizophrenia [37].
In summary, the Slc6a5 mutant mice provide a useful model for
examining activity-dependent developmental processes and in that
context, suggest the presence of an activity-dependent, myogenin-
independent mechanism for regulating AChR expression in
muscle. The behavioral changes observed in heterozygotes are
also indicative of a function for Slc6a5 in behaviors controlled by
higher brain regions. The affected circuits underlying these
changes can now be explored both anatomically and pharmaco-
logically based on Slc6a5 expression and this functional demon-
stration of its relevance.
Materials and Methods
Animal studies
All studies were performed in accordance with the Guide for the
Care and Use of Laboratory Animals, and all procedures were
approved by The Jackson Laboratory Animal Care and Use
Committee, comprehensive protocol #01026, approval date Oct.
28, 2010. Strains, ages, and the number of animals examined in
given experiments are provided in the text and figure legends at
appropriate points. All experiments, except the mapping of the
mutation and the synapse elimination count (described below),
were performed with mice from the original NOD CD8 colony.
Animals were provided food (NIH 6% diet) and water ad libitum
and were kept on a standard 14-10 light-dark cycle.
Mapping of the new mutation
Ovaries of affected, P10 females from the NOD CD8 colony
(NOD.CgPrkdc
scidEmv30
b/Dvs) were transplanted in NOD SCID
recipient females. Recipient females were mated with DBA/2J
males and the F1 obligate heterozygotes were mated together.
Affected and non-affected mice of the F2 generation were
collected. When it appeared that the mutation partially segregated
with the white coat color linked to the tyrosinase gene, at 94.6 Mb
on chromosome 7, we searched the Mouse Genome Database
(Blake et al., 2011) (http://www.informatics.jax.org) for existing
mutations with neurological phenotypes that would already have
been reported on chromosome 7 between 30 and 150 Mb. The
phenotype of the knock-out of Slc6a5 closely resembled the new
mutation; therefore, we selected MIT SSLP markers around this
locus that are polymorphic between NOD and DBA/2 (see
Fig. 1.D). Genotyping 16 affected and 19 unaffected mice of the F2
progeny with these markers confirmed that the mutation
segregated with D7MIT27 at 51.2 Mb, 6 Mb away from Slc6a5.
A separate colony on the original inbred NOD mice was also
maintained for use in behavioral studies.
Primer Sequences for the characterization of the
mutation
The primers used for the sequencing of Slc6a5 mRNA were
ex1F : TTT GAT TGG TTT TAC AGT GAA GTA A and ex2R :
CTC GTC CTC CGG TAT GGT AG, amplifying a 689 bp
product ; ex2F : GTG GCC ACC ACT ACC ATA CC and ex7R :
AAT CAC CCA AGC CAA GAA AA, amplifying a 699 bp
product;ex7F:CTTTTCTTGGCTTGGGTGATandex13R:
GGT GTC CAC AAG CTG AAA CA, amplifying a 705 bp
product, and ex13F : TGA TCA CAC AGG GTG GAA TTT and
ex16R : GAG GAA GCC CGG GAG TAA TA, amplifying a
578 bpproduct.Theinsertionsite oftheMusD retrotransposonwas
determined by PCR on genomic DNA using int5F : AGA GCA
CTG AAG AGG CAA GC and MusR : GAA CGG TTC GAC
TGA GAA GG. For the amplification of the retrotransposon
by primers in intron 5 flanking the insertion site we used int5F
and int5R : GGG AAC TTC CTT TCC AGT CAG. The fol-
lowing primers were used to genotype for the mutation from
genomic DNA: Slc6a5 F (in intron 5, 59 of the insertion) : TGC
TCT CTT TTG GTC TTA TTC AAA, Slc6a5 WT R (in intron 5,
39 of the insertion) : CCA GTA GGT GGT GCT GTT GG and
Slc6a5 Mut R (in the retrotransposon) : TAG ACG GGG CAA
AAG AAG AA.
Immunocytochemistry
Reagents used consist of a guinea-pig anti-GLYT2 antibody
(Millipore, AB1773) and the Vectastain ABC Kit for Guinea Pig
IgGs (Vector Laboratories, PK-4007). After intracardiac perfusion
with PBS followed by 2% paraformaldehyde in PBS, spinal cords
and brains were harvested and post-fixed overnight in 2%
paraformaldehyde in PBS at 4 degrees. Tissues were dehydrated
and paraffin-embedded. 4 um-thick sections were de-paraffinized
and rehydrated in a xylene/ethanol series. An antigen-retrieval
step was required, consisting of heating the slides in citrate
buffer (10 mM, pH 6) in a microwave twice to a boiling point.
Endogenous peroxidases were blocked with Peroxo-Block (Invitro-
gen, 00-2015) for 3 min. Sections were incubated overnight at 4
degrees in the primary antibody diluted in 0.5% BSA in PBS, then
at room temperature in a biotinylated goat anti-guinea pig
antibody for 30 min, in the avidin/HRP conjugate for 45 min and
stained with DAB for 5 min. Sections were rinsed, nuclei were
counterstained in hematoxylin for 3 min, dehydrated and
mounted in Permount medium (Fisher Scientific).
Western blotting
Spinal cords were collected and homogenized in 250 mM
sucrose, 50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT and
protease inhibitors (Complete protease inhibitor cocktail, Roche),
at 4 degrees. Lysates were centrifuged at 6.000 g for 15 min and
the supernatant was ultracentrifuged at 100.000 g for one hour.
The pellet was solubilized in 20 mM Tris pH 7.4, 0.4 M NaCl,
15% glycerol, 1 mM DTT, 1.5% Triton X100. 50 mg of proteins
(as measured by the BCA method (BCA Protein Assay, Pierce)
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buffer and used for the western-blot following usual protocols.
Membranes were probed with a guinea pig anti-GLYT2 primary
antibody and an HRP-conjugate anti-guinea pig secondary
antibody (Millipore, AP108P). For a loading control, membranes
were stripped in 25 mM glycine (pH 2) for one hour and re-
probed with a mouse anti-beta-dystroglycan primary antibody
(MANDAG2, clone 7D110) and an HRP-conjugate anti-mouse
secondary antibody (Perkin Elmer).
The monoclonal antibody MANDAG2 developed by G.E.
Morris was obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and maintained
by The University of Iowa, Department of Biology, Iowa City, IA
52242.
NMJ visualization
To visualize NMJs, Slc6a5 mutants were bred to Thy1-YFP16, a
transgenic line expressing YFP in all motor neurons from
embryonic development onward [75]. Ribcages were fixed
overnight in 2% paraformaldehyde in PBS at 4 degrees, the
triangularis sterni was dissected out and stained in Alexa-594-
conjugated alpha-bungarotoxin (Invitrogen) to label AChR
clusters. Quantification of the polyinnervation was performed
blind of the genotypes on a Nikon microscope, with a 63X
objective. NMJs were called monoinnervated when only one axon
terminal was seen in apposition with the AChR plaque, and
polyinnervated when 2 or more axon terminals where seen. An
average of 50 NMJs per mouse and 8 mice per age group and
genotype were examined.
Quantitative PCR
Diaphragms were collected and stored overnight in RNALater
(Applied Biosystems, AM7021). Endplates, visualized as the
central part of the muscle containing the innervating nerves, were
dissected. RNAs were extracted with the TRIzol protocol
(Invitrogen, 15596-026) and assessed for purity on a Nanodrop
spectrophotometer (ThermoScientific). Only samples with a 260/
280 ratio above 1.9 were used. 500 ng of total RNAs were reverse-
transcribed with oligo dT priming following manufacturer
instructions (SuperScript
TM III Reverse Transcriptase, Invitrogen,
18080-093) and 50 or 10 ng of cDNA were used per quantitative
PCR reaction. qPCR reactions were run with the SYBR-Green
PCR master mix (Applied Biosystem) on a 7500 Real-Time PCR
System (Applied Biosystems).
Primers were selected from PrimerBank [76], for GAPDH
(PrimerBank ID 6679937a1, AGG TCG GTG TGA ACG GAT
TTG and TGT AGA CCA TGT AGT TGA GGT CA),
myogenin (PrimerBank ID 13654247a1, GAG ACA TCC CCC
TAT TTC TAC CA and GCT CAG TCC GCT CAT AGC C)
and the AChR subunits alpha, epsilon and gamma (resp.
PrimerBank ID 31542391a1, CTC TCG ACT GTT CTC
CTG CTG and GTA GAC CCA CGG TGA CTT GTA ;
PrimerBank ID 6752950a3, GGC AGC TTT TAC CGA GAA
TGG and CGG CGG ATG ATG AGC GTA TAG ; PrimerBank
ID 31982815a3, CCC GAC GGT TGT ATC TAC TGG and
CTG GGA TTG GAA GAT GAG GGA). We verified that all
primers presented the same amplification efficiency for a range of
1 to 100 ng of cDNA per PCR reaction and used the DDCt
method to represent the fold change of each target mRNA in the
mutant samples compared to the wild-type one. Error bars
represent the extreme values of the fold change incorporating the
standard deviations of the mutant DCts. Muscles were harvested
from mice at P5 (n=5) or at P12 and P16 (4 and 3 samples resp.),
which showed no differences and were pooled and reported as
‘‘two weeks’’ samples.
Hot plate
3 to 5 month old naı ¨ve mice were tested only once on a dry bath
incubator (Fisher Scientific) plate set at 50 degrees. We measured
the response latency until the first hind paw flick was observed.
The experiment was stopped after the first response or after 30 sec
on the plate if no response was observed in this time frame.
Home Cage Monitoring
We used the Home Cage Scan system from CleverSys [59–61]
consisting of 4 cameras monitoring simultaneously 4 mice
individually housed in 4 separate 13618629 cm acrylic cages
on a 12:12 light:dark cycle. The room was lit by white lights from
6 am to 6 pm, and red lights from 6 pm to 6 am. Mice were
introduced in the monitoring cages one hour before dark.
Recordings were made from 1 hour before dark to 1 hour after
dark and analysis of the recorded behavior was made on the
12 hours of the dark cycle. Random bouts of the movies were
inspected after the experiment to ascertain the accuracy of the
behaviors called by the recognition software. 6 female mice per
genotype and age group in the defined NOD genetic background
were monitored for 2 successive nights. Results are presented as
the average percent of time where a given behavior was observed.
The behaviors presented in this article did not show any significant
variation between the first and the second night. In Fig. 5.A,
‘‘vertical activity’’ (1) regroups the behaviors Come Down, Come
Down From Partially Reared, Come Down To Partially Reared,
Hang Cuddled, Hang Vertically From Hang Cuddled, Hang
Vertically From Rear Up, Land Vertically, Rear Up, Rear up
From Partially Reared, Rear up To Partially Reared, Remain
Hang Cuddled, and Remain Hang Vertically; ‘‘horizontal
activity’’ (2) regroups the behaviors Turn, Walk Left, Walk Right,
Walk Slowly; and ‘‘food search/consumption’’ (3) regroups the
behaviors Chew, Dig, Eat (from the grain holder).
Open Field
The openfield (BiObserve) consists of an open square area
(240624 0) divided in 5 concentric zones (each approximately 4.8 0
wide) monitored by a camera placed above for 10 min per mouse.
Movies were analyzed with the BiObserve software and the track
length and time per zone were used for analysis.
Elevated plus maze
The elevated plus maze (Columbus Instruments) consists of 4
arms (11.75’’ long x 2’’ wide), 2 of which are open and 2 closed (by
6’’ high walls) on a metal platform about 51’’ off the floor. Naı ¨ve
mice were placed in the center of the 4 arms while number of
entries per arm, time spent and track length in each arm, number
of fecal boli and urination were recorded for a 5 minute period.
Entries were recorded as number of photo-beam breaks. Time
spent in each arm and track length were recorded with a CCD
camera above the plus-maze coupled to the BiObserve analysis
software, and all other parameters were measured manually.
Average velocity was calculated by dividing the track length by the
time spent in each arm.
Statistics
Differences were considered significant for statistical tests
returning p values ,0.05 (*), ,0.01 (**) and ,0.001 (***).
For the analysis of the synapse elimination counts in Fig. 3.B,
the Wilcoxon signed-rank test was applied on the average values of
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take in better consideration the variations inside each age/
genotype group, individual observations were pooled into a P3-P5
and a P6-P9 groups with the percent of polyinnervated NMJs
expressed as a percent of the average in the control group at each
age, and analyzed with the Mann-Whitney test. The age groups
were determined based on the observations that the overt spastic
phenotype is not visible before P5 in the mutants and that there
seem to be no difference in the time course of the synapse
elimination before P5, but a difference after P5.
Statistical significance for the quantitative PCR results in
Fig. 3.D was tested by comparing the DCts to GAPDH for each
target in the control and mutant groups with the Mann-Whitney
test. The Mann-Whitney test was used to compare the times spent
performing the indicated behaviors (Fig. 5.B) and the average
velocities in the elevated plus maze (Fig. 6.D).
Supporting Information
Movie S1 The handling induced spasticity of a Slc6a5 mutant
pup from the original mapping cross. Note the affected mouse is
albino. In response to stimulation, the mouse becomes rigid and
spastic, consistent with overactivation of motor neurons in the
absence of glycinergic inhibition in the spinal cord.
(WMV)
Acknowledgments
We would also like to thank Drs. Zhong-wei Zhang and Da-Ting Lin for
comments on the manuscript, and the scientific services at The Jackson
Laboratory, particularly the Light Microscopy and Histology services.
Author Contributions
Conceived and designed the experiments: LPB RWB. Performed the
experiments: LPB HDC KEM. Analyzed the data: LPB RWB.
Contributed reagents/materials/analysis tools: DVS. Wrote the paper:
LPB RWB.
References
1. Ornung G, Ottersen OP, Cullheim S, Ulfhake B (1998) Distribution of
glutamate-, glycine- and GABA-immunoreactive nerve terminals on dendrites in
the cat spinal motor nucleus. Exp Brain Res 118: 517–532.
2. Rekling JC, Funk GD, Bayliss DA, Dong XW, Feldman JL (2000) Synaptic
control of motoneuronal excitability. Physiol Rev 80: 767–852.
3. Renshaw B (1946) Central effects of centripetal impulses in axons of spinal
ventral roots. J Neurophysiol 9: 191–204.
4. Eccles JC, Fatt P, Koketsu K (1954) Cholinergic and inhibitory synapses in a
pathway from motor-axon collaterals to motoneurones. J Physiol (Lond) 126:
524–562.
5. Alvarez FJ, Dewey DE, McMillin P, Fyffe RE (1999) Distribution of cholinergic
contacts on Renshaw cells in the rat spinal cord: a light microscopic study.
J Physiol (Lond 515(Pt 3): 787–797.
6. Fyffe RE (1991) Glycine-like immunoreactivity in synaptic boutons of identified
inhibitory interneurons in the mammalian spinal cord. Brain Research 547:
163–166. doi:10.1016/0006-8993(91)90590-R.
7. Holstege JC, Bongers CM (1991) A glycinergic projection from the ventromedial
lower brainstem to spinal motoneurons. An ultrastructural double labeling study
in rat. Brain Res 566: 308–315.
8. Todd AJ, Sullivan AC (1990) Light microscope study of the coexistence of
GABA-like and glycine-like immunoreactivities in the spinal cord of the rat.
J Comp Neurol 296: 496–505. doi:10.1002/cne.902960312.
9. Todd AJ (2010) Neuronal circuitry for pain processing in the dorsal horn. Nat
Rev Neurosci 11: 823–836. doi:10.1038/nrn2947.
10. Beyer C, Roberts LA, Komisaruk BR (1985) Hyperalgesia induced by altered
glycinergic activity at the spinal cord. Life Sci 37: 875–882.
11. Sherman SE, Loomis CW (1996) Strychnine-sensitive modulation is selective for
non-noxious somatosensory input in the spinal cord of the rat. Pain 66: 321–330.
doi:10.1016/0304-3959(96)03063-1.
12. Zeilhofer HU (2005) The glycinergic control of spinal pain processing. Cell Mol
Life Sci 62: 2027–2035. doi:10.1007/s00018-005-5107-2.
13. Jursky F, Nelson N (1995) Localization of glycine neurotransmitter transporter
(GLYT2) reveals correlation with the distribution of glycine receptor.
J Neurochem 64: 1026–1033.
14. Dugue ´ GP, Dumoulin A, Triller A, Dieudonne ´ S (2005) Target-dependent use
of co-released inhibitory transmitters at central synapses. J Neurosci 25:
6490–6498. doi:10.1523/JNEUROSCI.1500-05.2005.
15. Holopainen I, Kontro P (1989) Uptake and release of glycine in cerebellar
granule cells and astrocytes in primary culture: Potassium-stimulated release
from granule cells is calcium-dependent. J Neurosci Res 24: 374–383.
doi:10.1002/jnr.490240306.
16. Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor — five
years on. Trends in Pharmacological Sciences 14: 20–25. doi:10.1016/0165-
6147(93)90108-V.
17. Ahmadi S (2003) Facilitation of Spinal NMDA Receptor Currents by Spillover
of Synaptically Released Glycine. Science 300: 2094–2097. doi:10.1126/
science.1083970.
18. Betz H, Laube B (2006) Glycine receptors: recent insights into their structural
organization and functional diversity. J Neurochem 97: 1600–1610.
doi:10.1111/j.1471-4159.2006.03908.x.
19. Betz H, Gomeza J, Armsen W, Scholze P, Eulenburg V (2006) Glycine
transporters: essential regulators of synaptic transmission. Biochem Soc Trans
34: 55–58. doi:10.1042/BST0340055.
20. Rousseau F, Aubrey KR, Supplisson S (2008) The Glycine Transporter GlyT2
Controls the Dynamics of Synaptic Vesicle Refilling in Inhibitory Spinal Cord
Neurons. Journal of Neuroscience 28: 9755–9768. doi:10.1523/JNEUR-
OSCI.0509-08.2008.
21. Gomeza J, Hu ¨lsmann S, Ohno K, Eulenburg V, Szo ¨ke K, et al. (2003)
Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine
uptake in glycinergic inhibition. Neuron 40: 785–796.
22. Harvey RJ (2008) A critical role for glycine transporters in hyperexcitability
disorders. Front Mol Neurosci 1, Available: http://www.frontiersin.org/Journal/
Abstract.aspx?s=702&name=molecular_neuroscience&ART_DOI=10.3389/
neuro.02.001.2008. Accessed 5 July 2011.
23. Gomeza J, Ohno K, Hu ¨lsmann S, Armsen W, Eulenburg V, et al. (2003)
Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype
and postnatal lethality. Neuron 40: 797–806.
24. Eulenburg V, Becker K, Gomeza J, Schmitt B, Becker C-M, et al. (2006)
Mutations within the human GLYT2 (SLC6A5) gene associated with
hyperekplexia. Biochem Biophys Res Commun 348: 400–405. doi:10.1016/
j.bbrc.2006.07.080.
25. Rees MI, Harvey K, Pearce BR, Chung S-K, Duguid IC, et al. (2006) Mutations
in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of
human startle disease. Nature Genetics 38: 801–806. doi:10.1038/ng1814.
26. Charlier C, Coppieters W, Rollin F, Desmecht D, Agerholm JS, et al. (2008)
Highly effective SNP-based association mapping and management of recessive
defects in livestock. Nature Genetics 40: 449–454. doi:10.1038/ng.96.
27. Gill JL, Capper D, Vanbellinghen J-F, Chung S-K, Higgins RJ, et al. (2011)
Startle disease in Irish wolfhounds associated with a microdeletion in the glycine
transporter GlyT2 gene. Neurobiol Dis 43: 184–189. doi:10.1016/
j.nbd.2011.03.010.
28. Feng G, Tintrup H, Kirsch J, Nichol MC, Kuhse J, et al. (1998) Dual
requirement for gephyrin in glycine receptor clustering and molybdoenzyme
activity. Science 282: 1321–1324.
29. Reiss J, Gross-Hardt S, Christensen E, Schmidt P, Mendel RR, et al. (2001) A
mutation in the gene for the neurotransmitter receptor-clustering protein
gephyrin causes a novel form of molybdenum cofactor deficiency. Am J Hum
Genet 68: 208–213. doi:10.1086/316941.
30. Rees MI, Harvey K, Ward H, White JH, Evans L, et al. (2003) Isoform
heterogeneity of the human gephyrin gene (GPHN), binding domains to the
glycine receptor, and mutation analysis in hyperekplexia. J Biol Chem 278:
24688–24696. doi:10.1074/jbc.M301070200.
31. Harvey RJ (2004) GlyR 3: An Essential Target for Spinal PGE2-Mediated
Inflammatory Pain Sensitization. Science 304: 884–887. doi:10.1126/science.
1094925.
32. Xiong W, Cheng K, Cui T, Godlewski G, Rice KC, et al. (2011) Cannabinoid
potentiation of glycine receptors contributes to cannabis-induced analgesia.
Nature Chemical Biology 7: 296–303. doi:10.1038/nchembio.552.
33. McCool BA, Chappell A (2007) Strychnine and taurine modulation of
amygdala-associated anxiety-like behavior is ‘‘state’’ dependent. Behav Brain
Res 178: 70–81. doi:10.1016/j.bbr.2006.12.002.
34. Tsai GE, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, et al.
(2004) Gene knockout of glycine transporter 1: characterization of the behavioral
phenotype. Proc Natl Acad Sci USA 101: 8485–8490. doi:10.1073/
pnas.0402662101.
35. Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, et al. (2006) Disruption of
glycine transporter 1 restricted to forebrain neurons is associated with a
procognitive and antipsychotic phenotypic profile. J Neurosci 26: 3169–3181.
doi:10.1523/JNEUROSCI.5120-05.2006.
36. Jamra RA, Villela AW, Klein K, Becker T, Schulze TG, et al. (2006) No
association between genetic variants at the GLYT2 gene and bipolar affective
Novel Behavioral Phenotypes in Slc6a5 Mutant Mice
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30217disorder and schizophrenia. Psychiatr Genet 16: 91. doi:10.1097/01.ypg.
0000199450.07786.ab.
37. Deng X, Sagata N, Takeuchi N, Tanaka M, Ninomiya H, et al. (2008)
Association study of polymorphisms in the neutral amino acid transporter genes
SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with
schizophrenia. BMC Psychiatry 8: 58. doi:10.1186/1471-244X-8-58.
38. Rodgers RJ, Howard K, Stewart S, Waring P, Wright FL (2010) Anxioselective
profile of glycineB receptor partial agonist, D-cycloserine, in plus-maze-naı ¨ve
but not plus-maze-experienced mice. Eur J Pharmacol 646: 31–37. doi:10.1016/
j.ejphar.2010.08.005.
39. Mager DL, Freeman JD (2000) Novel mouse type D endogenous proviruses and
ETn elements share long terminal repeat and internal sequences. J Virol 74:
7221–7229.
40. Zafra F, Arago ´n C, Olivares L, Danbolt NC, Gime ´nez C, et al. (1995) Glycine
transporters are differentially expressed among CNS cells. J Neurosci 15:
3952–3969.
41. Zeilhofer HU, Studler B, Arabadzisz D, Schweizer C, Ahmadi S, et al. (2005)
Glycinergic neurons expressing enhanced green fluorescent protein in bacterial
artificial chromosome transgenic mice. J Comp Neurol 482: 123–141.
doi:10.1002/cne.20349.
42. Jansen JK, Fladby T (1990) The perinatal reorganization of the innervation of
skeletal muscle in mammals. Prog Neurobiol 34: 39–90.
43. O’Brien RA, Ostberg AJ, Vrbova ´ G (1978) Observations on the elimination of
polyneuronal innervation in developing mammalian skeletal muscle. J Physiol
(Lond) 282: 571–582.
44. Personius KE, Balice-Gordon RJ (2000) Activity-dependent editing of
neuromuscular synaptic connections. Brain Res Bull 53: 513–522.
45. Mishina M, Takai T, Imoto K, Noda M, Takahashi T, et al. (1986) Molecular
distinction between fetal and adult forms of muscle acetylcholine receptor.
Nature 321: 406–411. doi:10.1038/321406a0.
46. Witzemann V, Barg B, Nishikawa Y, Sakmann B, Numa S (1987) Differential
regulation of muscle acetylcholine receptor gamma- and epsilon-subunit
mRNAs. FEBS Lett 223: 104–112.
47. Gu Y, Hall ZW (1988) Immunological evidence for a change in subunits of the
acetylcholine receptor in developing and denervated rat muscle. Neuron 1:
117–125.
48. Missias AC, Mudd J, Cunningham JM, Steinbach JH, Merlie JP, et al. (1997)
Deficient development and maintenance of postsynaptic specializations in
mutant mice lacking an ‘‘adult’’ acetylcholine receptor subunit. Development
124: 5075–5086.
49. Missias AC, Chu GC, Klocke BJ, Sanes JR, Merlie JP (1996) Maturation of the
acetylcholine receptor in skeletal muscle: regulation of the AChR gamma-to-
epsilon switch. Dev Biol 179: 223–238. doi:10.1006/dbio.1996.0253.
50. Martinou JC, Merlie JP (1991) Nerve-dependent modulation of acetylcholine
receptor epsilon-subunit gene expression. J Neurosci 11: 1291–1299.
51. Prody CA, Merlie JP (1991) A developmental and tissue-specific enhancer in the
mouse skeletal muscle acetylcholine receptor alpha-subunit gene regulated by
myogenic factors. J Biol Chem 266: 22588–22596.
52. Numberger M, Du ¨rr I, Kues W, Koenen M, Witzemann V (1991) Different
mechanisms regulate muscle-specific AChR gamma- and epsilon-subunit gene
expression. EMBO J 10: 2957–2964.
53. Eftimie R, Brenner HR, Buonanno A (1991) Myogenin and MyoD join a family
of skeletal muscle genes regulated by electrical activity. Proc Natl Acad Sci USA
88: 1349–1353.
54. Witzemann V, Sakmann B (1991) Differential regulation of MyoD and
myogenin mRNA levels by nerve induced muscle activity. FEBS Lett 282:
259–264.
55. Eftimie R, Brenner HR, Buonanno A (1991) Myogenin and MyoD join a family
of skeletal muscle genes regulated by electrical activity. Proc Natl Acad Sci USA
88: 1349–1353.
56. Duclert A, Piette J, Changeux JP (1991) Influence of innervation of myogenic
factors and acetylcholine receptor alpha-subunit mRNAs. Neuroreport 2: 25–28.
57. Neville CM, Schmidt M, Schmidt J (1992) Response of myogenic determination
factors to cessation and resumption of electrical activity in skeletal muscle: a
possible role for myogenin in denervation supersensitivity. Cell Mol Neurobiol
12: 511–527.
58. Haranishi Y, Hara K, Terada T, Nakamura S, Sata T (2010) The
antinociceptive effect of intrathecal administration of glycine transporter-2
inhibitor ALX1393 in a rat acute pain model. Anesth Analg 110: 615–621.
doi:10.1213/ANE.0b013e3181c7ebbb.
59. Steele AD, Jackson WS, King OD, Lindquist S (2007) The power of automated
high-resolution behavior analysis revealed by its application to mouse models of
Huntington’s and prion diseases. Proceedings of the National Academy of
Sciences 104: 1983–1988. doi:10.1073/pnas.0610779104.
60. Kalueff A (2009) Experimental animal models in neurobehavioral research. New
York: Nova Science Publishers.
61. Martinowich K, Schloesser RJ, Jimenez DV, Weinberger DR, Lu B (2011)
Activity-dependent brain-derived neurotrophic factor expression regulates
cortistatin-interneurons and sleep behavior. Mol Brain 4: 11. doi:10.1186/
1756-6606-4-11.
62. Prut L (2003) The open field as a paradigm to measure the effects of drugs on
anxiety-like behaviors: a review. European Journal of Pharmacology 463: 3–33.
doi:10.1016/S0014-2999(03)01272-X.
63. Kano H, Kurahashi H, Toda T (2007) Genetically regulated epigenetic
transcriptional activation of retrotransposon insertion confers mouse dactyla-
plasia phenotype. Proc Natl Acad Sci USA 104: 19034–19039. doi:10.1073/
pnas.0705483104.
64. Ribet D (2004) An active murine transposon family pair: Retrotransposition of
‘‘master’’ MusD copies and ETn trans-mobilization. Genome Research 14:
2261–2267. doi:10.1101/gr.2924904.
65. Budnik V, Zhong Y, Wu CF (1990) Morphological plasticity of motor axons in
Drosophila mutants with altered excitability. J Neurosci 10: 3754–3768.
66. Schuster CM, Davis GW, Fetter RD, Goodman CS (1996) Genetic dissection of
structural and functional components of synaptic plasticity. II. Fasciclin II
controls presynaptic structural plasticity. Neuron 17: 655–667.
67. Mosca TJ, Carrillo RA, White BH, Keshishian H (2005) Dissection of synaptic
excitability phenotypes by using a dominant-negative Shaker K+ channel
subunit. Proc Natl Acad Sci USA 102: 3477–3482. doi:10.1073/pnas.
0406164102.
68. Bradaia A (2004) Role of glial and neuronal glycine transporters in the control of
glycinergic and glutamatergic synaptic transmission in lamina X of the rat spinal
cord. The Journal of Physiology 559: 169–186. doi:10.1113/jphysiol.2004.
068858.
69. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with Reduced
NMDA Receptor Expression Display Behaviors Related to Schizophrenia. Cell
98: 427–436. doi:10.1016/S0092-8674(00)81972-8.
70. Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal A-M, Mutel V, et al.
(2002) Severe impairment of NMDA receptor function in mice carrying targeted
point mutations in the glycine binding site results in drug-resistant nonhabituat-
ing hyperactivity. J Neurosci 22: 6713–6723. doi:20026610.
71. Basu AC, Tsai GE, Ma C-L, Ehmsen JT, Mustafa AK, et al. (2008) Targeted
disruption of serine racemase affects glutamatergic neurotransmission and
behavior. Mol Psychiatry 14: 719–727. doi:10.1038/mp.2008.130.
72. Dawe GS, Hwang EH, Tan CH (2009) Pathophysiology and animal models of
schizophrenia. Ann Acad Med Singap 38: 425–426.
73. Labrie V, Roder JC (2010) The involvement of the NMDA receptor d-serine/
glycine site in the pathophysiology and treatment of schizophrenia. Neuro-
science & Biobehavioral Reviews 34: 351–372. doi:10.1016/j.neubiorev.2009.
08.002.
74. Monti JM, Monti D (2004) Sleep in schizophrenia patients and the effects of
antipsychotic drugs. Sleep Medicine Reviews 8: 133–148. doi:10.1016/S1087-
0792(02)00158-2.
75. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, et al. (2000)
Imaging neuronal subsets in transgenic mice expressing multiple spectral
variants of GFP. Neuron 28: 41–51.
76. Spandidos A, Wang X, Wang H, Seed B (2009) PrimerBank: a resource of
human and mouse PCR primer pairs for gene expression detection and
quantification. Nucleic Acids Research 38: D792–D799. doi:10.1093/nar/
gkp1005.
Novel Behavioral Phenotypes in Slc6a5 Mutant Mice
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30217